The Center for Biosimilars® recaps the top news for the week of April 1, 2019.
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of April 1.
Number 5: A new consensus report calls the nocebo effect underrecognized in the area of biosimilars and says that more research is needed on this important topic.
Number 4: Stakeholders testified before a House of Representatives subcommittee about the impact of the rising costs of insulin.
Number 3: A head-to-head study, published in The Lancet, has produced data that may help allay gastroenterologists’ concerns about using CT-P13 in Corhn disease.
Number 2: Sandoz announced that it has resubmitted its Biologics License Application for its pegfilgrastim biosimilar referencing Neulasta.
Number 1: Yet another class action lawsuit has been filed against AbbVie, maker of Humira. This time, Baltimore, Maryland, is suing both AbbVie and Amgen for delayed biosimilar competition.
Finally, last week, our e-newsletter asked whether you agree with the FDA’s decision to require 4-letter suffixes only for newly approved biologics and biosimlars.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.